Table II.
Characteristics of patients
| Characteristics | Propofol (n = 50) | M/M (n = 50) | P-value |
|---|---|---|---|
| Age [years] | 47 ±17 | 41 ±15 | 0.052 |
| Gender, M/F | 23/27 | 21/29 | 0.840 |
| BMI [kg/cm2] | 27.0 ±4.8 | 26.6 ±5.3 | 0.681 |
| ASA classification: | 0.256 | ||
| I | 35 | 40 | |
| II | 13 | 10 | |
| III | 2 | 0 | |
| Tobacco/alcohol use | 8 | 10 | 0.374 |
| Co-existing disease: | 18 | 15 | 0.523 |
| Cardiovascular disorders | 12 | 8 | |
| Diabetes mellitus | 2 | 3 | |
| Others | 6 | 8 | |
| Medical treatment: | 18 | 15 | 0.523 |
| Cardiovascular drugs | 12 | 8 | |
| Oral antidiabetics | 2 | 3 | |
| Others | 6 | 8 | |
| Operation history: | 19 | 18 | 0.682 |
| Gastrointestinal surgery | 5 | 8 | |
| Others | 15 | 11 | |
| Total drug dose [mg]: | |||
| Propofol | 88.0 ±26.1 | – | |
| Meperidine | – | 28.92 ±5.96 | |
| Midazolam | – | 3.61 ±0.91 | |
Data are given as mean ± SD or number and percent of cases. ASA – American Society of Anesthesiologists, BMI – body mass index, M/M: midazolam + meperidine.